David Lebovitz

Stock Analyst at Citigroup

(0.37)
# 1964
Out of 5,240 analysts
123
Total ratings
72.73%
Success rate
4.91%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Crinetics Pharmaceut...
Maintains: Strong Buy
70 74
37.06 99.68% 2 Nov 14, 2024
Biomarin Pharmaceuti...
Maintains: Neutral
93 81
63.73 27.1% 2 Oct 30, 2024
Madrigal Pharmaceuti...
Maintains: Buy
382 371
274.4 35.2% 3 Aug 8, 2024
Alnylam Pharmaceutic...
Maintains: Strong Buy
291 342
250.03 36.78% 30 Aug 2, 2024
Mirum Pharmaceutical...
Maintains: Strong Buy
37 38
44.7 -14.99% 1 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Sell
29 17
43.22 -60.67% 5 Oct 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
111 92
105.91 -13.13% 6 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
57 54
54.37 -0.68% 5 Aug 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
408 372
n/a n/a 5 May 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
11 10
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
38 35
33.49 4.51% 6 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
16 17
3.05 457.38% 11 Apr 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
12 11
3.77 191.78% 7 Feb 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
193 220
n/a n/a 5 Feb 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
50 500
n/a n/a 2 Dec 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 44
n/a n/a 10 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
194 199
135 47.41% 11 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
34 32
0.65 4823.08% 2 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
27 26
n/a n/a 2 Aug 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
119 129
n/a n/a 3 Mar 6, 2018